

We upgrade Aarti to BUY from Add and revise up our TP by 5% to Rs525 from Rs500 (25x Jun-27E EPS, on rollover); the revision is owing to the recent stock price correction and steep rise in gasoline-naphtha cracks which should raise demand for octane boosters and aid volume growth for MMA (Energy business). Aarti would deliver a decent performance within 2-3Y, on i) steady ramp-up in existing, under-utilized capacities; ii) certain macro tailwinds favoring the overall product basket; iii) gradual YoY recovery in coming quarters; iv) staying on track to achieve FY28 EBITDA guidance of Rs18-22bn. Overall performance would be buoyed by cost optimization measures (~18%), volume and margin ramp-up of existing assets (especially MMA; ~45%), and capex-driven growth (~38%). We bake in the middle-end of the FY28 EBITDA guidance, of~Rs20bn.

Decent ramp-up in capacities over the next few quarters

Aarti has significant potential from higher asset utilization which is likely to add to 45% of incremental EBITDA, basis guidance range of Rs8-12bn. Aarti's focus is to ramp-up its existing assets of NCB, DCB, and Hydrogenation to 85% in the near term from current utilization of ~75%. Aarti would benefit from increased order enquiries for MPDA from its US-based customers which would aid better utilization levels for PDA capacities, in our view. It has recently expanded its nitro toluene (NT) value chain, ethylation, and MMA capacities (in H2FY25) which will be ramped up in FY26. Thus, we expect gradual ramp-up tied up with demand growth which will lead to better operating leverage.

Macro tailwinds favoring the broader product basket

We believe that the current geopolitical situation and the agrochemical restocking shall benefit the company in ramping up its existing assets. The company is seeing incremental volume growth for agchem intermediates and downstream technical, while pricing is steady given demand-supply imbalance led by Chinese overcapacities. The US tariff situation may create new market opportunities for Aarti across agrochemicals, pharmaceuticals (higher demand for paracetamol), polymers, and additives (PDA value chain). Energy business outlook is expected to improve, on favorable gasoline-naphtha spreads, and see sequential growth in volume from Q2FY26, on a lower base.

On track to achieve FY28 EBITDA guidance of Rs18-22bn

Aarti will see sequential recovery in EBITDA YoY owing to 1) cost optimization initiatives, which are partially complete; 2) ramp of existing capacities with focus on the energy business; and 3) meaningful contribution from MPP and Zone 4 commercialization. Zone 4 capex would see staggered commissioning from H2FY26, starting with MPP, calcium chloride, and then chlorotoluene. FY26 capex guidance stands at Rs10bn (Zone 4: Rs8bn; maintenance: Rs2bn). Post-FY26, focus will be on capacity ramp-up, slow down in capex, and improving balance sheet ratios. Aarti expects debt/EBITDA of under-2.5x and RoCE above 15%. We bake in the middle-end of the FY28 EBITDA guidance, of Rs20bn.

Target Price – 12M	Jun-26
Change in TP (%)	5.0
Current Reco.	BUY
Previous Reco.	ADD
Upside/(Downside) (%)	18.0

Stock Data	AR TO IN
52-week High (Rs)	767
52-week Low (Rs)	344
Shares outstanding (mn)	362.5
Market-cap (Rs bn)	161
Market-cap (USD mn)	1,860
Net-debt, FY26E (Rs mn)	39,833.9
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	839.5
ADTV-3M (USD mn)	9.7
Free float (%)	0.0
Nifty-50	24,971.9
INR/USD	86.8


Shareholding, Mar-25

Promoters (%)	42.2
FPIs/MFs (%)	6.3/20.0

Price Performance

(%)	1M	3M	12M
Absolute	(5.1)	9.3	(37.2)
Rel. to Nifty	(5.6)	2.2	(40.9)

1-Year share price trend (Rs)



Aarti Industries: Financial Snapshot (Consolidated)

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	63,720	72,710	90,179	105,976	122,862
EBITDA	9,760	10,010	13,511	17,305	19,931
Adj. PAT	4,160	3,290	5,140	7,168	8,961
Adj. EPS (Rs)	11.5	9.1	14.2	19.8	24.8
EBITDA margin (%)	15.3	13.8	15.0	16.3	16.2
EBITDA growth (%)	(10.4)	2.6	35.0	28.1	15.2
Adj. EPS growth (%)	(23.7)	(20.9)	56.2	39.5	25.0
RoE (%)	8.1	6.0	8.8	11.2	12.6
RoIC (%)	9.5	8.6	9.4	10.2	11.4
P/E (x)	38.7	49.3	31.4	22.5	18.0
EV/EBITDA (x)	19.6	19.1	14.2	11.1	9.6
P/B (x)	3.0	2.9	2.7	2.4	2.1
FCFF yield (%)	(0.3)	(0.8)	(0.8)	4.4	5.1


Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded as


Exhibit 1: Capacity and utilization trends show significant upside, leading to operating leverage

Product groups	Capacity (KT; expanded period)	FY22	FY23	FY24	FY25	YoY	Q4FY24	Q3FY25	Q4FY25	YoY	QoQ	FY25 utilization
NCB	108 (from Q3FY24)	76.6	77.8	73.5	85.3	16%	18.8	22.9	23.9	27%	4%	79%
DCB	120	74.6	84.2	80.7	88.6	10%	24.4	20.8	20.4	-16%	-2%	74%
Hydrogenation	60	35.7	37.2	39.1	44.4	14%	10.5	11.3	11.6	10%	3%	74%
PDA	12	6.5	4.2	4.4	3.9	-11%	1.9	1.3	1.0	-47%	-23%	33%
NT	45 (from Q4FY25)	16	23.9	30.5	29.4	-4%	6.7	6.5	7.9	18%	22%	65%
Ethylation	25-30 (from Q4FY25)	7.2	11.9	10.5	14.5	38%	3.2	4.1	4.6	44%	12%	48%
MMA	200 (from Q3FY25)	23.1	37.8	89.3	123.0	38%	30.4	36.6	34.8	14%	-5%	62%


Source: Company, Emkay Research

Exhibit 2: Gasoline-Naphtha spreads improving; favorable for MMA

Source: Company, Bloomberg, Emkay Research

Exhibit 3: Aarti to clock revenue CAGR of 19% over FY25-28E


Source: Company, Emkay Research

Exhibit 4: Volume growth and cost optimization to lead to EBITDA growth

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

Exhibit 5: Mindful capex with stable cash flows for debt repayment



Source: Company, Emkay Research

Exhibit 6: Debt to remain under control with slowdown in capex and improving return ratios




Source: Company, Emkay Research

Exhibit 7: Specialty Chemicals companies – Peer valuations, a comparison


Peer (Domestic)	Rating	TP (Rs)	CMP (Rs)	P/E (x)		EV/E (x)		RoE (%)		
				FY26E	FY27E	FY26E	FY27E	FY25	FY26E	FY27E
SRF	ADD	3,250	3,033	43	32	25	20	10	16	18
PI Industries	REDUCE	3,650	4,152	37	32	26	23	18	16	16
Gujarat Fluorochemicals*	SELL	3,800	3,373	48	41	28	25	9	11	12
Deepak Nitrite	REDUCE	2,000	1,879	34	29	21	17	14	13	14
Navin Fluorine International	ADD	4,800	4,640	51	39	30	24	12	16	18
Atul	BUY	8,500	6,926	31	24	18	15	9	11	13
Aarti Industries	BUY	525	445	31	22	14	11	6	9	11
Epigral	BUY	2,450	1,738	18	14	11	9	23	20	21
Anupam Rasayan India*	ADD	900	1,143	80	41	34	22	3	6	10
GHCL	BUY	900	581	9	8	6	5	19	17	16
Vishnu Chemicals	BUY	600	536	23	18	14	11	16	15	17
Tata Chemicals	NR	NA	906	44	25	13	11	2	2	4
Vinati Organics	NR	NA	1,913	40	33	28	23	15	16	18
Deepak Fertilisers & Petrochem	NR	NA	1,548	18	14	10	8	16	16	18
Fine Organic Industries	NR	NA	4,718	33	31	25	22	20	18	16
Clean Science & Technology	NR	NA	1,434	46	36	32	25	21	21	22
Jubilant Ingrevia	NR	NA	724	37	29	20	16	9	10	12
Aether Industries	NR	NA	764	46	34	31	22	7	9	10
Archean Chemical Industries	NR	NA	620	21	16	14	11	12	17	20
Laxmi Organic Industries	NR	NA	192	31	24	14	11	7	8	10
Sudarshan Chemical Industries	NR	NA	1,245	31	34	18	16	12	19	17
Neogen Chemicals	NR	NA	1,598	68	36	28	16	7	7	12

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

Exhibit 8: One-year forward P/E

Source: Company, Emkay Research

Exhibit 9: One-year forward EV/EBITDA

Source: Company, Emkay Research

Aarti Industries: Consolidated Financials and Valuations

Profit & Loss

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	63,720	72,710	90,179	105,976	122,862
Revenue growth (%)	(3.7)	14.1	24.0	17.5	15.9
EBITDA	9,760	10,010	13,511	17,305	19,931
EBITDA growth (%)	(10.4)	2.6	35.0	28.1	15.2
Depreciation & Amortization	3,780	4,340	5,313	6,157	6,445
EBIT	5,980	5,670	8,198	11,148	13,487
EBIT growth (%)	(23.2)	(5.2)	44.6	36.0	21.0
Other operating income	-	-	-	-	-
Other income	80	140	140	140	140
Financial expense	2,110	2,750	2,928	2,855	2,426
PBT	3,950	3,060	5,410	8,433	11,201
Extraordinary items	0	(20)	0	0	0
Taxes	(210)	(230)	271	1,265	2,240
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	4,160	3,270	5,140	7,168	8,961
PAT growth (%)	(23.7)	(21.4)	57.2	39.5	25.0
Adjusted PAT	4,160	3,290	5,140	7,168	8,961
Diluted EPS (Rs)	11.5	9.1	14.2	19.8	24.8
Diluted EPS growth (%)	(23.7)	(20.9)	56.2	39.5	25.0
DPS (Rs)	1.5	1.0	1.4	2.0	2.5
Dividend payout (%)	13.0	11.0	10.0	10.0	10.0
EBITDA margin (%)	15.3	13.8	15.0	16.3	16.2
EBIT margin (%)	9.4	7.8	9.1	10.5	11.0
Effective tax rate (%)	(5.3)	(7.5)	5.0	15.0	20.0
NOPLAT (pre-IndAS)	6,298	6,096	7,788	9,476	10,789
Shares outstanding (mn)	362	362	362	362	362

Source: Company, Emkay Research

Cash flows

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	3,870	2,920	5,270	8,293	11,061
Others (non-cash items)	3,780	4,340	5,313	6,157	6,445
Taxes paid	(850)	60	(271)	(1,265)	(2,240)
Change in NWC	1,828	2,160	(4,832)	(2,696)	(2,882)
Operating cash flow	12,100	12,420	8,408	13,344	14,809
Capital expenditure	(12,761)	(13,880)	(10,000)	(5,000)	(5,000)
Acquisition of business	(58)	(250)	0	0	0
Interest & dividend income	-	-	-	-	-
Investing cash flow	(13,690)	(13,980)	(9,860)	(4,860)	(4,860)
Equity raised/(repaid)	(3)	0	0	0	0
Debt raised/(repaid)	6,900	2,250	2,303	(4,241)	(7,214)
Payment of lease liabilities	(227)	20	0	0	0
Interest paid	(2,110)	(2,750)	(2,928)	(2,855)	(2,426)
Dividend paid (incl tax)	(540)	(360)	(514)	(717)	(896)
Others	(47)	130	-	0	-
Financing cash flow	3,973	(710)	(1,139)	(7,814)	(10,536)
Net chg in Cash	2,383	(2,270)	(2,591)	671	(587)
OCF	12,100	12,420	8,408	13,344	14,809
Adj. OCF (w/o NWC chg.)	10,272	10,260	13,240	16,040	17,691
FCFF	(661)	(1,460)	(1,592)	8,344	9,809
FCFE	(2,771)	(4,210)	(4,520)	5,489	7,383
OCF/EBITDA (%)	124.0	124.1	62.2	77.1	74.3
FCFE/PAT (%)	(66.6)	(128.7)	(87.9)	76.6	82.4
FCFF/NOPLAT (%)	(10.5)	(23.9)	(20.4)	88.1	90.9

Source: Company, Emkay Research

Balance Sheet

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	1,810	1,810	1,810	1,810	1,810
Reserves & Surplus	51,080	54,240	58,866	65,317	73,381
Net worth	52,890	56,050	60,676	67,127	75,191
Minority interests	10	0	0	0	0
Non-current liab. & prov.	(1,440)	(2,180)	(2,180)	(2,180)	(2,180)
Total debt	35,640	37,890	40,193	35,951	28,738
Total liabilities & equity	87,100	91,760	98,688	100,898	101,749
Net tangible fixed assets	55,875	62,765	76,992	75,835	74,391
Net intangible assets	85	485	485	485	485
Net ROU assets	530	510	510	510	510
Capital WIP	12,290	14,540	5,000	5,000	5,000
Goodwill	0	0	0	0	0
Investments [JV/Associates]	230	480	480	480	480
Cash & equivalents	5,160	2,950	359	1,029	443
Current assets (ex-cash)	25,530	27,230	31,550	36,863	42,542
Current Liab. & Prov.	12,600	17,200	16,688	19,305	22,102
NWC (ex-cash)	12,930	10,030	14,862	17,558	20,441
Total assets	87,100	91,760	98,688	100,898	101,749
Net debt	30,480	34,940	39,834	34,922	28,295
Capital employed	87,100	91,760	98,688	100,898	101,749
Invested capital	68,890	73,280	92,340	93,879	95,316
BVPS (Rs)	146.1	154.8	167.6	185.4	207.7
Net Debt/Equity (x)	0.6	0.6	0.7	0.5	0.4
Net Debt/EBITDA (x)	3.1	3.5	2.9	2.0	1.4
Interest coverage (x)	2.9	2.1	2.8	4.0	5.6
RoCE (%)	7.3	6.4	8.6	11.1	13.2

Source: Company, Emkay Research

Valuations and key Ratios

Y/E March	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	38.7	49.3	31.4	22.5	18.0
EV/CE(x)	2.2	2.0	1.9	1.9	1.8
P/B (x)	3.0	2.9	2.7	2.4	2.1
EV/Sales (x)	3.0	2.6	2.1	1.8	1.6
EV/EBITDA (x)	19.6	19.1	14.2	11.1	9.6
EV/EBIT(x)	32.0	33.8	23.4	17.2	14.2
EV/IC (x)	2.8	2.6	2.1	2.0	2.0
FCFF yield (%)	(0.3)	(0.8)	(0.8)	4.4	5.1
FCFE yield (%)	(1.7)	(2.6)	(2.8)	3.4	4.6
Dividend yield (%)	0.3	0.2	0.3	0.4	0.6
DuPont-RoE split					
Net profit margin (%)	6.5	4.5	5.7	6.8	7.3
Total asset turnover (x)	0.8	0.8	1.0	1.1	1.2
Assets/Equity (x)	1.6	1.6	1.6	1.6	1.4
RoE (%)	8.1	6.0	8.8	11.2	12.6
DuPont-RoIC					
NOPLAT margin (%)	9.9	8.4	8.6	8.9	8.8
IC turnover (x)	1.0	1.0	1.1	1.1	1.3
RoIC (%)	9.5	8.6	9.4	10.2	11.4
Operating metrics					
Core NWC days	74.1	50.4	60.2	60.5	60.7
Total NWC days	74.1	50.4	60.2	60.5	60.7
Fixed asset turnover	0.9	0.9	0.9	1.0	1.1
Opex-to-revenue (%)	23.8	22.2	23.2	23.0	23.2

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


June 23, 2025 | 5

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
09-May-25	452	500	Add	Meet Vora
06-Apr-25	374	450	Add	Meet Vora
03-Feb-25	453	525	Add	Meet Vora
11-Nov-24	440	525	Add	Meet Vora
24-Sep-24	589	675	Buy	Meet Vora
27-Aug-24	640	800	Buy	Meet Vora
13-Aug-24	621	800	Buy	Meet Vora
14-Jul-24	706	800	Buy	Meet Vora
07-Jun-24	635	800	Buy	Meet Vora
13-May-24	669	800	Buy	Meet Vora
07-Apr-24	696	750	Buy	Meet Vora
26-Feb-24	672	750	Buy	Meet Vora
09-Feb-24	663	750	Buy	Meet Vora
18-Jan-24	612	750	Buy	Meet Vora

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of June 23, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of June 23, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 23, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

**Seshadri
Kumar
Sen**

Digitally signed
by Seshadri
Kumar Sen
Date: 2025.06.23
22:15:14 +05'30'

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a